Stock VXRT VAXART, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Vaxart, Inc.

Equities

VXRT

US92243A2006

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
0.6229 USD -5.38% Intraday chart for Vaxart, Inc. -9.54% +8.75%
Jul. 08 HilleVax to discontinue development of norovirus vaccine for infants; shares plummet RE
Jun. 14 Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet
RE
Vaxart Provides Business Update
AQ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday
MT
B. Riley Raises Price Target on Vaxart to $2.50 From $2, Maintains Buy Rating
MT
Vaxart Receives $453 Million for Phase 2b Trial of Covid-19 Oral Pill Vaccine Candidate
MT
Vaxart Launches $40 Million Share Offering; Shares Rise Pre-Bell
MT
Vaxart Announces $40 Million Underwritten Offering of Common Stock
AQ
US government to fund up to $500 mln for studies on oral, nasal COVID vaccines
RE
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
AQ
Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
CI
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024
Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (VXRT) VAXART Reports Q1 Revenue $2.2M, vs. Street Est of $0.8M
MT
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
AQ
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
AQ
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
CI
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
AQ
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
AQ
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VXRT Stock
  4. News Vaxart, Inc.